Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease

Abstract Introduction Pulmonary arterial hypertension (PAH) in patients with congenital heart disease (CHD) usually has a homogeneous pressure distribution. More rarely, complex CHD patients have segmental PAH. This is often post-surgically. The characteristics of these patients and their responsive...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cardiology 2013-03, Vol.164 (1), p.106-110
Hauptverfasser: Schuuring, Mark J, Bouma, Berto J, Cordina, Rachael, Gatzoulis, Michael A, Budts, Werner, Mullen, Mary P, Vis, Jeroen C, Celermajer, David, Mulder, Barbara J.M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 110
container_issue 1
container_start_page 106
container_title International journal of cardiology
container_volume 164
creator Schuuring, Mark J
Bouma, Berto J
Cordina, Rachael
Gatzoulis, Michael A
Budts, Werner
Mullen, Mary P
Vis, Jeroen C
Celermajer, David
Mulder, Barbara J.M
description Abstract Introduction Pulmonary arterial hypertension (PAH) in patients with congenital heart disease (CHD) usually has a homogeneous pressure distribution. More rarely, complex CHD patients have segmental PAH. This is often post-surgically. The characteristics of these patients and their responsiveness to specific pulmonary vasodilator therapy have not been described. Methods Seven adults with segmental PAH complicating CHD were treated at 3 specialized adult CHD centers between January 2006 and December 2010. Clinical characteristics, six minute walking distances (6MWD), laboratory tests and images were obtained from medical records and the responses to Bosentan, an endothelin-1 receptor antagonist, were assessed. Results All patients (mean age 32 (23–42) years, five females) had a primary diagnosis pulmonary atresia (PA), four with major aortopulmonary collateral arteries (MAPCAs). Four segmental PAH patients had a right pulmonary artery stenosis, two a left pulmonary artery stenosis and one a unilateral MAPCA stenosis. All patients were symptomatic (functional class II or III) and bosentan was started empirically. Bosentan treatment led to a significant improvement in functional class compared to baseline (1.7 ± 0.5 versus 2.4 ± 0.5; p < 0.01). Mean 6MWD (available in 6 patients) increased by 62 m (22–150 m) from 386 ± 135 to 448 ± 133 m ( p = 0.03) after 12 months treatment. Most improvement was seen in patients with low baseline 6MWD. Higher baseline exercise heart rate was significantly associated with lesser improvement in 6MWD ( r = − 0.91 p = 0.01). Laboratory results did not change after initiation of bosentan treatment. Conclusion This small retrospective case series suggested a significant improvement of functional class and exercise capacity after bosentan treatment in patients with segmental PAH. These findings warrant a prospective study of the potential benefit of selective pulmonary vasodilator therapy in these complex patients. Therefore, we call on treating physicians to share similar cases.
doi_str_mv 10.1016/j.ijcard.2011.06.084
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1314705308</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167527311006243</els_id><sourcerecordid>1314705308</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-30cab32f1e25232f44a70153f320e2e1cde81a8de7c04936ca91ad9c37b1eeae3</originalsourceid><addsrcrecordid>eNqFks-L1DAUgIMo7rj6H4j0InhpfS9Jm85FkGV1hQUPrjchZJLXndQ2HZNWmf_elBlX8OLpvcP3fn08xl4iVAjYvO0r31sTXcUBsYKmglY-YhtslSxR1fIx22RMlTVX4oI9S6kHALndtk_ZBUfVCEC1Yd_uIpl5pDAXU1ckul9TMxSHZRinYOKxMHGmHPbHA-UsJD-FwofCuGWYU_HLz_vCTuGegl_r9pT5wvlEJtFz9qQzQ6IX53jJvn64vru6KW8_f_x09f62tFKquRRgzU7wDonXPEcpjQKsRSc4ECe0jlo0rSNl8wGisWaLxm2tUDskMiQu2ZtT30OcfiyUZj36ZGkYTKBpSRoFSgW1gDaj8oTaOKUUqdOH6Md8p0bQq1fd65NXvXrV0OjsNZe9Ok9YdiO5h6I_IjPw-gyYZM3QRROsT385hU3dKsjcuxNH2cdPT1En6ylYcj6SnbWb_P82-beBHXzweeZ3OlLqpyWG7FqjTlyD_rL-wPoCiAANl0L8Bk1srmE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1314705308</pqid></control><display><type>article</type><title>Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Schuuring, Mark J ; Bouma, Berto J ; Cordina, Rachael ; Gatzoulis, Michael A ; Budts, Werner ; Mullen, Mary P ; Vis, Jeroen C ; Celermajer, David ; Mulder, Barbara J.M</creator><creatorcontrib>Schuuring, Mark J ; Bouma, Berto J ; Cordina, Rachael ; Gatzoulis, Michael A ; Budts, Werner ; Mullen, Mary P ; Vis, Jeroen C ; Celermajer, David ; Mulder, Barbara J.M</creatorcontrib><description>Abstract Introduction Pulmonary arterial hypertension (PAH) in patients with congenital heart disease (CHD) usually has a homogeneous pressure distribution. More rarely, complex CHD patients have segmental PAH. This is often post-surgically. The characteristics of these patients and their responsiveness to specific pulmonary vasodilator therapy have not been described. Methods Seven adults with segmental PAH complicating CHD were treated at 3 specialized adult CHD centers between January 2006 and December 2010. Clinical characteristics, six minute walking distances (6MWD), laboratory tests and images were obtained from medical records and the responses to Bosentan, an endothelin-1 receptor antagonist, were assessed. Results All patients (mean age 32 (23–42) years, five females) had a primary diagnosis pulmonary atresia (PA), four with major aortopulmonary collateral arteries (MAPCAs). Four segmental PAH patients had a right pulmonary artery stenosis, two a left pulmonary artery stenosis and one a unilateral MAPCA stenosis. All patients were symptomatic (functional class II or III) and bosentan was started empirically. Bosentan treatment led to a significant improvement in functional class compared to baseline (1.7 ± 0.5 versus 2.4 ± 0.5; p &lt; 0.01). Mean 6MWD (available in 6 patients) increased by 62 m (22–150 m) from 386 ± 135 to 448 ± 133 m ( p = 0.03) after 12 months treatment. Most improvement was seen in patients with low baseline 6MWD. Higher baseline exercise heart rate was significantly associated with lesser improvement in 6MWD ( r = − 0.91 p = 0.01). Laboratory results did not change after initiation of bosentan treatment. Conclusion This small retrospective case series suggested a significant improvement of functional class and exercise capacity after bosentan treatment in patients with segmental PAH. These findings warrant a prospective study of the potential benefit of selective pulmonary vasodilator therapy in these complex patients. Therefore, we call on treating physicians to share similar cases.</description><identifier>ISSN: 0167-5273</identifier><identifier>EISSN: 1874-1754</identifier><identifier>DOI: 10.1016/j.ijcard.2011.06.084</identifier><identifier>PMID: 21763017</identifier><identifier>CODEN: IJCDD5</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Adult ; Antihypertensive Agents - therapeutic use ; Biological and medical sciences ; Bosentan ; Cardiology. Vascular system ; Cardiovascular ; Congenital heart disease ; Congenital heart diseases. Malformations of the aorta, pulmonary vessels and vena cava ; Familial Primary Pulmonary Hypertension ; Female ; Heart ; Heart Defects, Congenital - complications ; Humans ; Hypertension, Pulmonary - complications ; Hypertension, Pulmonary - drug therapy ; Male ; Medical sciences ; Pneumology ; Pulmonary arterial hypertension ; Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases ; Retrospective Studies ; Segmental ; Sulfonamides - therapeutic use ; Young Adult</subject><ispartof>International journal of cardiology, 2013-03, Vol.164 (1), p.106-110</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2011 Elsevier Ireland Ltd</rights><rights>2014 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-30cab32f1e25232f44a70153f320e2e1cde81a8de7c04936ca91ad9c37b1eeae3</citedby><cites>FETCH-LOGICAL-c447t-30cab32f1e25232f44a70153f320e2e1cde81a8de7c04936ca91ad9c37b1eeae3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0167527311006243$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=27165870$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21763017$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schuuring, Mark J</creatorcontrib><creatorcontrib>Bouma, Berto J</creatorcontrib><creatorcontrib>Cordina, Rachael</creatorcontrib><creatorcontrib>Gatzoulis, Michael A</creatorcontrib><creatorcontrib>Budts, Werner</creatorcontrib><creatorcontrib>Mullen, Mary P</creatorcontrib><creatorcontrib>Vis, Jeroen C</creatorcontrib><creatorcontrib>Celermajer, David</creatorcontrib><creatorcontrib>Mulder, Barbara J.M</creatorcontrib><title>Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease</title><title>International journal of cardiology</title><addtitle>Int J Cardiol</addtitle><description>Abstract Introduction Pulmonary arterial hypertension (PAH) in patients with congenital heart disease (CHD) usually has a homogeneous pressure distribution. More rarely, complex CHD patients have segmental PAH. This is often post-surgically. The characteristics of these patients and their responsiveness to specific pulmonary vasodilator therapy have not been described. Methods Seven adults with segmental PAH complicating CHD were treated at 3 specialized adult CHD centers between January 2006 and December 2010. Clinical characteristics, six minute walking distances (6MWD), laboratory tests and images were obtained from medical records and the responses to Bosentan, an endothelin-1 receptor antagonist, were assessed. Results All patients (mean age 32 (23–42) years, five females) had a primary diagnosis pulmonary atresia (PA), four with major aortopulmonary collateral arteries (MAPCAs). Four segmental PAH patients had a right pulmonary artery stenosis, two a left pulmonary artery stenosis and one a unilateral MAPCA stenosis. All patients were symptomatic (functional class II or III) and bosentan was started empirically. Bosentan treatment led to a significant improvement in functional class compared to baseline (1.7 ± 0.5 versus 2.4 ± 0.5; p &lt; 0.01). Mean 6MWD (available in 6 patients) increased by 62 m (22–150 m) from 386 ± 135 to 448 ± 133 m ( p = 0.03) after 12 months treatment. Most improvement was seen in patients with low baseline 6MWD. Higher baseline exercise heart rate was significantly associated with lesser improvement in 6MWD ( r = − 0.91 p = 0.01). Laboratory results did not change after initiation of bosentan treatment. Conclusion This small retrospective case series suggested a significant improvement of functional class and exercise capacity after bosentan treatment in patients with segmental PAH. These findings warrant a prospective study of the potential benefit of selective pulmonary vasodilator therapy in these complex patients. Therefore, we call on treating physicians to share similar cases.</description><subject>Adult</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bosentan</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular</subject><subject>Congenital heart disease</subject><subject>Congenital heart diseases. Malformations of the aorta, pulmonary vessels and vena cava</subject><subject>Familial Primary Pulmonary Hypertension</subject><subject>Female</subject><subject>Heart</subject><subject>Heart Defects, Congenital - complications</subject><subject>Humans</subject><subject>Hypertension, Pulmonary - complications</subject><subject>Hypertension, Pulmonary - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pneumology</subject><subject>Pulmonary arterial hypertension</subject><subject>Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases</subject><subject>Retrospective Studies</subject><subject>Segmental</subject><subject>Sulfonamides - therapeutic use</subject><subject>Young Adult</subject><issn>0167-5273</issn><issn>1874-1754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFks-L1DAUgIMo7rj6H4j0InhpfS9Jm85FkGV1hQUPrjchZJLXndQ2HZNWmf_elBlX8OLpvcP3fn08xl4iVAjYvO0r31sTXcUBsYKmglY-YhtslSxR1fIx22RMlTVX4oI9S6kHALndtk_ZBUfVCEC1Yd_uIpl5pDAXU1ckul9TMxSHZRinYOKxMHGmHPbHA-UsJD-FwofCuGWYU_HLz_vCTuGegl_r9pT5wvlEJtFz9qQzQ6IX53jJvn64vru6KW8_f_x09f62tFKquRRgzU7wDonXPEcpjQKsRSc4ECe0jlo0rSNl8wGisWaLxm2tUDskMiQu2ZtT30OcfiyUZj36ZGkYTKBpSRoFSgW1gDaj8oTaOKUUqdOH6Md8p0bQq1fd65NXvXrV0OjsNZe9Ok9YdiO5h6I_IjPw-gyYZM3QRROsT385hU3dKsjcuxNH2cdPT1En6ylYcj6SnbWb_P82-beBHXzweeZ3OlLqpyWG7FqjTlyD_rL-wPoCiAANl0L8Bk1srmE</recordid><startdate>20130320</startdate><enddate>20130320</enddate><creator>Schuuring, Mark J</creator><creator>Bouma, Berto J</creator><creator>Cordina, Rachael</creator><creator>Gatzoulis, Michael A</creator><creator>Budts, Werner</creator><creator>Mullen, Mary P</creator><creator>Vis, Jeroen C</creator><creator>Celermajer, David</creator><creator>Mulder, Barbara J.M</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130320</creationdate><title>Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease</title><author>Schuuring, Mark J ; Bouma, Berto J ; Cordina, Rachael ; Gatzoulis, Michael A ; Budts, Werner ; Mullen, Mary P ; Vis, Jeroen C ; Celermajer, David ; Mulder, Barbara J.M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-30cab32f1e25232f44a70153f320e2e1cde81a8de7c04936ca91ad9c37b1eeae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bosentan</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular</topic><topic>Congenital heart disease</topic><topic>Congenital heart diseases. Malformations of the aorta, pulmonary vessels and vena cava</topic><topic>Familial Primary Pulmonary Hypertension</topic><topic>Female</topic><topic>Heart</topic><topic>Heart Defects, Congenital - complications</topic><topic>Humans</topic><topic>Hypertension, Pulmonary - complications</topic><topic>Hypertension, Pulmonary - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pneumology</topic><topic>Pulmonary arterial hypertension</topic><topic>Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases</topic><topic>Retrospective Studies</topic><topic>Segmental</topic><topic>Sulfonamides - therapeutic use</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schuuring, Mark J</creatorcontrib><creatorcontrib>Bouma, Berto J</creatorcontrib><creatorcontrib>Cordina, Rachael</creatorcontrib><creatorcontrib>Gatzoulis, Michael A</creatorcontrib><creatorcontrib>Budts, Werner</creatorcontrib><creatorcontrib>Mullen, Mary P</creatorcontrib><creatorcontrib>Vis, Jeroen C</creatorcontrib><creatorcontrib>Celermajer, David</creatorcontrib><creatorcontrib>Mulder, Barbara J.M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schuuring, Mark J</au><au>Bouma, Berto J</au><au>Cordina, Rachael</au><au>Gatzoulis, Michael A</au><au>Budts, Werner</au><au>Mullen, Mary P</au><au>Vis, Jeroen C</au><au>Celermajer, David</au><au>Mulder, Barbara J.M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease</atitle><jtitle>International journal of cardiology</jtitle><addtitle>Int J Cardiol</addtitle><date>2013-03-20</date><risdate>2013</risdate><volume>164</volume><issue>1</issue><spage>106</spage><epage>110</epage><pages>106-110</pages><issn>0167-5273</issn><eissn>1874-1754</eissn><coden>IJCDD5</coden><abstract>Abstract Introduction Pulmonary arterial hypertension (PAH) in patients with congenital heart disease (CHD) usually has a homogeneous pressure distribution. More rarely, complex CHD patients have segmental PAH. This is often post-surgically. The characteristics of these patients and their responsiveness to specific pulmonary vasodilator therapy have not been described. Methods Seven adults with segmental PAH complicating CHD were treated at 3 specialized adult CHD centers between January 2006 and December 2010. Clinical characteristics, six minute walking distances (6MWD), laboratory tests and images were obtained from medical records and the responses to Bosentan, an endothelin-1 receptor antagonist, were assessed. Results All patients (mean age 32 (23–42) years, five females) had a primary diagnosis pulmonary atresia (PA), four with major aortopulmonary collateral arteries (MAPCAs). Four segmental PAH patients had a right pulmonary artery stenosis, two a left pulmonary artery stenosis and one a unilateral MAPCA stenosis. All patients were symptomatic (functional class II or III) and bosentan was started empirically. Bosentan treatment led to a significant improvement in functional class compared to baseline (1.7 ± 0.5 versus 2.4 ± 0.5; p &lt; 0.01). Mean 6MWD (available in 6 patients) increased by 62 m (22–150 m) from 386 ± 135 to 448 ± 133 m ( p = 0.03) after 12 months treatment. Most improvement was seen in patients with low baseline 6MWD. Higher baseline exercise heart rate was significantly associated with lesser improvement in 6MWD ( r = − 0.91 p = 0.01). Laboratory results did not change after initiation of bosentan treatment. Conclusion This small retrospective case series suggested a significant improvement of functional class and exercise capacity after bosentan treatment in patients with segmental PAH. These findings warrant a prospective study of the potential benefit of selective pulmonary vasodilator therapy in these complex patients. Therefore, we call on treating physicians to share similar cases.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>21763017</pmid><doi>10.1016/j.ijcard.2011.06.084</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0167-5273
ispartof International journal of cardiology, 2013-03, Vol.164 (1), p.106-110
issn 0167-5273
1874-1754
language eng
recordid cdi_proquest_miscellaneous_1314705308
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adult
Antihypertensive Agents - therapeutic use
Biological and medical sciences
Bosentan
Cardiology. Vascular system
Cardiovascular
Congenital heart disease
Congenital heart diseases. Malformations of the aorta, pulmonary vessels and vena cava
Familial Primary Pulmonary Hypertension
Female
Heart
Heart Defects, Congenital - complications
Humans
Hypertension, Pulmonary - complications
Hypertension, Pulmonary - drug therapy
Male
Medical sciences
Pneumology
Pulmonary arterial hypertension
Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases
Retrospective Studies
Segmental
Sulfonamides - therapeutic use
Young Adult
title Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T11%3A22%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20segmental%20pulmonary%20artery%20hypertension%20in%20adults%20with%20congenital%20heart%20disease&rft.jtitle=International%20journal%20of%20cardiology&rft.au=Schuuring,%20Mark%20J&rft.date=2013-03-20&rft.volume=164&rft.issue=1&rft.spage=106&rft.epage=110&rft.pages=106-110&rft.issn=0167-5273&rft.eissn=1874-1754&rft.coden=IJCDD5&rft_id=info:doi/10.1016/j.ijcard.2011.06.084&rft_dat=%3Cproquest_cross%3E1314705308%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1314705308&rft_id=info:pmid/21763017&rft_els_id=S0167527311006243&rfr_iscdi=true